In addition to the possible therapy of resistant cancers associated with HSP over-expression, the pharmacological control of stress-induced HSPs, molecular chaperones in particular, holds promise in the modulation of inflammation, protein misfolding diseases and aging in general. This evidence concerns the gene HSP90B2P and proteostasis deficiencies.